… Author links open overlay panel Jordan J. Lancaster PhD a b c , Pablo Sanchez MD a ,
Giuliana G. Repetti BA a , Elizabeth Juneman MD a b , Amitabh C. Pandey MD a , Ikeotunye R. …

Resulting from a various etiologies, the most notable remains ischemia; heart failure (HF)
manifests as the common end pathway of many cardiovascular processes and remains among …

… Author links open overlay panel Jordan J. Lancaster MS a b c , Elizabeth Juneman MD a
b , Sarah A. Arnce MMS, PA-C a b , Nicholle M. Johnson BS a b , Yexian Qin PhD d , Russell …

Granulocyte macrophage colony-stimulating factor (GM-CSF) promotes infarct expansion
and inappropriate collagen synthesis in a myocardial infarction (MI). This study was designed …

Heart failure (HF) post-myocardial infarction (MI) presents with increased vulnerability to
monomorphic ventricular tachycardia (mmVT). To appropriately evaluate new therapies for …

In swine models, there are well-established protocols for creating a closed-chest myocardial
infarction (MI) as well as protocols for characterization of cardiac function with cardiac …

Background. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
are under preclinical investigation as a cell-based therapy for heart failure post-myocardial …

Background: Poloxamer-188 (P-188) is a biological membrane sealant that prevents the
unregulated entry of Ca 2+ into cardiomyocytes and has been shown to have the ability to act …

Circ Heart Fail. 2018; 11: e005425. DOI: 10.1161/CIRCHEARTFAILURE. 118.005425 October
2018 2 functional benefit, which may be because of (1) lack of structural support, and (2) …

This review will outline cell-based therapy for heart failure focusing on tissue engineering to
deliver cells to the damaged heart. We will present an overview of the central approaches …